- Security Type
- Common Stock
- Categories
- Healthcare/Medical
- Min Investment
- $596
- Location
-
Carlsbad, CA
- Expected Close Date
- August 18, 2022
- Amount Raised
- $34,539
- Target Raise
- $10K-$1M
- No. Investors
- 45
- Security Price
- $6.62
- Valuation
- $100,000,000
- Number of Employees
- 2
- Cash
- $111,900
- Revenue
- $0
- Short Term Debt
- $7,524,097
- Cost of Goods
- $0
- Long Term Debt
- $441,014
- Net Income
- $-2,416,916
Company Description
TargaZyme is pioneering the next frontier of cancer medicine with the development of therapeutics that harnesses the power of a patient’s own immune system without the toxic chemotherapies, radiation, radical surgery or other toxic cancer drugs that make up today’s standard of care. TargaZyme is currently pre-revenue and in the R&D stage with our two breakthrough approaches: TZ101, a Phase-3 ready product, and TZ102, which is currently being prepared for clinical or human-patient trials.
Perks
StartEngine OWNERS Exclusive Click here to learn more
$331+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
Friends and Family Early Birds
Invest within the first week and receive 10% Bonus Shares
2
days
5
hours
33
mins
5
secs
$5,000+ Investment
$5,000+ Invest $5,000+ and receive 5% Bonus Shares
$10,000+ Investment
$10,000+ Invest $10,000+ and receive 10% Bonus Shares
$331+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
Friends and Family Early Birds
Invest within the first week and receive 10% Bonus Shares
2
days
5
hours
33
mins
5
secs
$5,000+ Investment
$5,000+ Invest $5,000+ and receive 5% Bonus Shares
$10,000+ Investment
$10,000+ Invest $10,000+ and receive 10% Bonus Shares
Key Deal Facts
A single dose of our novel patented medicine TZ101 was shown to improve survival of terminally ill cancer patients from 64% post-100 days of transplant to 78% post-100 days of transplant by preventing various diseases such as infections, GvHD, hemorrhaging, and stem cell engraftment failure in a Phase 2 clinical (human) trial at M D Anderson Center in Texas in 2015..
TargaZyme has been awarded over 38 worldwide patents, with over 40 patent-pending applications, and multiple orphan drug awards.
We have received $50m+ in funding to date, of which, $40m+ originated from highly prestigious medical awards. The team has worked with leading medical centers including MD Anderson Cancer Center, University of Pennsylvania Medical Center, Yale Medical Center, Harvard University Medical School, and Cleveland Clinic.
Security Description
Common stock is a security that represents ownership in a corporation.